All > Graft Vs Host Disease

Tacrolimus for Graft-versus-Host Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Graft-versus-Host Disease+2 MoreTacrolimus - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study whether the addition of BMS-986004 to standard of care Sirolimus-based immunosuppression is safe and effective.

Eligible Conditions
  • Graft-versus-Host Disease
  • Acute Graft-versus-Host Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
ApoGraft
1
Neihulizumab
1
MSCTC-0010 Dose Escalation

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 1 year post HCT

1 year post HCT
Chronic Graft-versus Host Disease Through 1 Year Post HCT
Glucocorticoid Exposure
Incidence of Grade II-IV Acute Graft-versus Host Disease
Malignancy Relapse Post-HCT
Neutrophil and Platelet Engraftment
Non-relapse Mortality
Overall Survival (OS)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
ApoGraft
1
Neihulizumab
1
MSCTC-0010 Dose Escalation

Trial Design

1 Treatment Group

Combination Therapy
1 of 1

Experimental Treatment

36 Total Participants · 1 Treatment Group

Primary Treatment: Tacrolimus · No Placebo Group · Phase 1

Combination TherapyExperimental Group · 3 Interventions: Tacrolimus, Sirolimus, BMS-986004 · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tacrolimus
FDA approved
Sirolimus
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year post hct

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
503 Previous Clinical Trials
125,953 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,500 Previous Clinical Trials
3,927,486 Total Patients Enrolled
Farhad Khimani, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a hematologic malignancy or blood disorder requiring allogeneic HCT.
You have a KPS score of 80% or higher.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top